BRIEF published on 03/26/2025 at 22:10, 10 months 4 days ago Abivax publishes its 2024 financial reports Biotechnology AMF Abivax Financial Reports DRY
PRESS RELEASE published on 03/26/2025 at 22:05, 10 months 4 days ago Abivax publishes financial reports with the French and U.S. securities regulatory agencies Abivax publishes financial reports with French and U.S. securities regulatory agencies. The company filed its Universal Registration Document and Annual Report for 2024 Abivax Financial Reports Regulatory Agencies U.S. Securities French
BRIEF published on 03/24/2025 at 08:35, 10 months 6 days ago Abivax Publishes its Financial Results for 2024 Financial Results Biotechnology Research And Development Treasury Clinical Trials
PRESS RELEASE published on 03/24/2025 at 08:30, 10 months 6 days ago Abivax Announces Full Year 2024 Financial Results Abivax announces full year 2024 financial results, cash balance of EUR 144.2M, ABTECT trial progress. CEO optimistic about 2025 milestones and financial outlook Financial Results Cash Position Abivax ABTECT Trial Clinical Progress
BRIEF published on 03/14/2025 at 15:21, 10 months 16 days ago JP Morgan Chase Reduces Stake in ABIVAX Actions Abivax Regulation Threshold Crossing JP Morgan Chase
BRIEF published on 03/13/2025 at 12:43, 10 months 17 days ago JP Morgan Crosses Threshold in ABIVAX Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF published on 02/25/2025 at 18:05, 11 months 5 days ago ABIVAX: Information on capital and voting rights as of January 31, 2025 Euronext Paris Share Capital Voting Rights Abivax Finances
BRIEF published on 02/21/2025 at 08:35, 11 months 9 days ago Abivax to Hold Expert Webcast on Ulcerative Colitis Abivax Obefazimod Ulcerative Colitis Clinical Trial Webcast Event
PRESS RELEASE published on 02/21/2025 at 08:30, 11 months 9 days ago Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Abivax to host Key Opinion Leader (KOL) webcast featuring Dr. David Rubin on March 17, 2025, discussing ulcerative colitis treatment landscape and ABTECT Phase 3 Trial Abivax Ulcerative Colitis Webcast ABTECT Phase 3 Trial Key Opinion Leader
BRIEF published on 02/18/2025 at 10:08, 11 months 12 days ago Crossing of threshold at ABIVAX: statement from Sofinnova Voting Rights Abivax Threshold Crossing Product Development Sofinnova Partners
Published on 01/31/2026 at 03:15, 4 hours 2 minutes ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 4 hours 57 minutes ago Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 5 hours 37 minutes ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 8 hours 17 minutes ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 02:45, 4 hours 32 minutes ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 9 hours 17 minutes ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 11 hours 7 minutes ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 11 hours 8 minutes ago Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 11 hours 10 minutes ago Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 17:45, 13 hours 32 minutes ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 1 day 13 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 13 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 13 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025
